The impact of tacrolimus levels on acute GVHD and transplant outcomes in haploidentical hematopoietic stem cell transplantation: A retrospective analysis

The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively a...

Full description

Saved in:
Bibliographic Details
Published inCell transplantation Vol. 34; p. 9636897251366368
Main Authors Nikoloudis, Alexander, Buxhofer-Ausch, Veronika, Kunte, Ameya, Groiss, Christina, Mair, Lorenz, Aichinger, Christoph, Binder, Michaela, Hasengruber, Petra, Kaynak, Emine, Wipplinger, Dagmar, Milanov, Robert, Strassl, Irene, Stiefel, Olga, Machherndl-Spandl, Sigrid, Rumpold, Holger, Weltermann, Ansgar, Petzer, Andreas, Clausen, Johannes
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.08.2025
Sage Publications Ltd
SAGE Publishing
Subjects
Adolescent
Adult
Blood levels
Cyclophosphamide
Female
Graft vs Host Disease - blood
Graft vs Host Disease - drug therapy
Graft-versus-host reaction
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic stem cells
Humans
Immunosuppressive Agents - therapeutic use
Lymphocytes T
Male
Middle Aged
Multivariate analysis
Mycophenolic acid
Original
Retrospective Studies
Stem cell transplantation
Tacrolimus
Tacrolimus - blood
Tacrolimus - therapeutic use
Transplantation, Haploidentical - methods
Treatment Outcome
Young Adult
tacrolimus
haploidentical transplantation with posttransplant cyclophosphamide and tacrolimus mycophenolate mofetil
acute graft-versus-host-disease
Online AccessGet full text
ISSN0963-6897
1555-3892
1555-3892
DOI10.1177/09636897251366368

Cover

Abstract The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively analyzed 161 T-cell–replete haplo-HSCT with PTCy, TAC, and mycophenolate-mofetil. TAC trough levels from weeks 1–2 (w1/2) and weeks 3–4 (w3/4) posttransplant were categorized as “Low” or “High” using a threshold of 10 ng/ml. Outcomes assessed included grade III–IV acute graft-versus-host-disease (aGVHD), nonrelapse mortality (NRM), relapse, and overall survival (OS). Multivariate analyses controlled for relevant patient and transplant factors. Higher w1/2 TAC (≥10 ng/ml) in weeks 1–2 had no association with aGVHD III/IV (35% vs. 35%, P = 0.71). Higher TAC levels during w3/4 were associated with a trend toward decreased aGVHD III–IV incidence (8% vs. 20%; P = 0.09). Multivariate analysis confirmed w3/4 TAC levels as protective against aGVHD III/IV (sub-Hazard Ratio [sHR] = 0.83, 95% CI: 0.70–0.98, P = 0.03) and NRM (sHR = 0.82, 95% CI: 0.71–0.95, P = 0.01), while w1/2 TAC levels had no significant impact on the above outcomes. TAC levels did not significantly impact OS or relapse. We conclude that following PTCy-based haplo-HSCT, higher TAC levels during weeks 3–4 may decrease aGVHD and NRM. Graphical Abstract
AbstractList The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively analyzed 161 T-cell–replete haplo-HSCT with PTCy, TAC, and mycophenolate-mofetil. TAC trough levels from weeks 1–2 (w1/2) and weeks 3–4 (w3/4) posttransplant were categorized as “Low” or “High” using a threshold of 10 ng/ml. Outcomes assessed included grade III–IV acute graft-versus-host-disease (aGVHD), nonrelapse mortality (NRM), relapse, and overall survival (OS). Multivariate analyses controlled for relevant patient and transplant factors. Higher w1/2 TAC (≥10 ng/ml) in weeks 1–2 had no association with aGVHD III/IV (35% vs. 35%, P = 0.71). Higher TAC levels during w3/4 were associated with a trend toward decreased aGVHD III–IV incidence (8% vs. 20%; P = 0.09). Multivariate analysis confirmed w3/4 TAC levels as protective against aGVHD III/IV (sub-Hazard Ratio [sHR] = 0.83, 95% CI: 0.70–0.98, P = 0.03) and NRM (sHR = 0.82, 95% CI: 0.71–0.95, P = 0.01), while w1/2 TAC levels had no significant impact on the above outcomes. TAC levels did not significantly impact OS or relapse. We conclude that following PTCy-based haplo-HSCT, higher TAC levels during weeks 3–4 may decrease aGVHD and NRM.
The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively analyzed 161 T-cell–replete haplo-HSCT with PTCy, TAC, and mycophenolate-mofetil. TAC trough levels from weeks 1–2 (w1/2) and weeks 3–4 (w3/4) posttransplant were categorized as “Low” or “High” using a threshold of 10 ng/ml. Outcomes assessed included grade III–IV acute graft-versus-host-disease (aGVHD), nonrelapse mortality (NRM), relapse, and overall survival (OS). Multivariate analyses controlled for relevant patient and transplant factors. Higher w1/2 TAC (≥10 ng/ml) in weeks 1–2 had no association with aGVHD III/IV (35% vs. 35%, P = 0.71). Higher TAC levels during w3/4 were associated with a trend toward decreased aGVHD III–IV incidence (8% vs. 20%; P = 0.09). Multivariate analysis confirmed w3/4 TAC levels as protective against aGVHD III/IV (sub-Hazard Ratio [sHR] = 0.83, 95% CI: 0.70–0.98, P = 0.03) and NRM (sHR = 0.82, 95% CI: 0.71–0.95, P = 0.01), while w1/2 TAC levels had no significant impact on the above outcomes. TAC levels did not significantly impact OS or relapse. We conclude that following PTCy-based haplo-HSCT, higher TAC levels during weeks 3–4 may decrease aGVHD and NRM. Graphical Abstract
The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively analyzed 161 T-cell–replete haplo-HSCT with PTCy, TAC, and mycophenolate-mofetil. TAC trough levels from weeks 1–2 (w1/2) and weeks 3–4 (w3/4) posttransplant were categorized as “Low” or “High” using a threshold of 10 ng/ml. Outcomes assessed included grade III–IV acute graft-versus-host-disease (aGVHD), nonrelapse mortality (NRM), relapse, and overall survival (OS). Multivariate analyses controlled for relevant patient and transplant factors. Higher w1/2 TAC (≥10 ng/ml) in weeks 1–2 had no association with aGVHD III/IV (35% vs. 35%, P = 0.71). Higher TAC levels during w3/4 were associated with a trend toward decreased aGVHD III–IV incidence (8% vs. 20%; P = 0.09). Multivariate analysis confirmed w3/4 TAC levels as protective against aGVHD III/IV (sub-Hazard Ratio [sHR] = 0.83, 95% CI: 0.70–0.98, P = 0.03) and NRM (sHR = 0.82, 95% CI: 0.71–0.95, P = 0.01), while w1/2 TAC levels had no significant impact on the above outcomes. TAC levels did not significantly impact OS or relapse. We conclude that following PTCy-based haplo-HSCT, higher TAC levels during weeks 3–4 may decrease aGVHD and NRM. Graphical Abstract
The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively analyzed 161 T-cell-replete haplo-HSCT with PTCy, TAC, and mycophenolate-mofetil. TAC trough levels from weeks 1-2 (w1/2) and weeks 3-4 (w3/4) posttransplant were categorized as "Low" or "High" using a threshold of 10 ng/ml. Outcomes assessed included grade III-IV acute graft-versus-host-disease (aGVHD), nonrelapse mortality (NRM), relapse, and overall survival (OS). Multivariate analyses controlled for relevant patient and transplant factors. Higher w1/2 TAC (≥10 ng/ml) in weeks 1-2 had no association with aGVHD III/IV (35% vs. 35%, = 0.71). Higher TAC levels during w3/4 were associated with a trend toward decreased aGVHD III-IV incidence (8% vs. 20%; = 0.09). Multivariate analysis confirmed w3/4 TAC levels as protective against aGVHD III/IV (sub-Hazard Ratio [sHR] = 0.83, 95% CI: 0.70-0.98, = 0.03) and NRM (sHR = 0.82, 95% CI: 0.71-0.95, = 0.01), while w1/2 TAC levels had no significant impact on the above outcomes. TAC levels did not significantly impact OS or relapse. We conclude that following PTCy-based haplo-HSCT, higher TAC levels during weeks 3-4 may decrease aGVHD and NRM.
The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively analyzed 161 T-cell-replete haplo-HSCT with PTCy, TAC, and mycophenolate-mofetil. TAC trough levels from weeks 1-2 (w1/2) and weeks 3-4 (w3/4) posttransplant were categorized as "Low" or "High" using a threshold of 10 ng/ml. Outcomes assessed included grade III-IV acute graft-versus-host-disease (aGVHD), nonrelapse mortality (NRM), relapse, and overall survival (OS). Multivariate analyses controlled for relevant patient and transplant factors. Higher w1/2 TAC (≥10 ng/ml) in weeks 1-2 had no association with aGVHD III/IV (35% vs. 35%, P = 0.71). Higher TAC levels during w3/4 were associated with a trend toward decreased aGVHD III-IV incidence (8% vs. 20%; P = 0.09). Multivariate analysis confirmed w3/4 TAC levels as protective against aGVHD III/IV (sub-Hazard Ratio [sHR] = 0.83, 95% CI: 0.70-0.98, P = 0.03) and NRM (sHR = 0.82, 95% CI: 0.71-0.95, P = 0.01), while w1/2 TAC levels had no significant impact on the above outcomes. TAC levels did not significantly impact OS or relapse. We conclude that following PTCy-based haplo-HSCT, higher TAC levels during weeks 3-4 may decrease aGVHD and NRM.The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) is incompletely investigated. We retrospectively analyzed 161 T-cell-replete haplo-HSCT with PTCy, TAC, and mycophenolate-mofetil. TAC trough levels from weeks 1-2 (w1/2) and weeks 3-4 (w3/4) posttransplant were categorized as "Low" or "High" using a threshold of 10 ng/ml. Outcomes assessed included grade III-IV acute graft-versus-host-disease (aGVHD), nonrelapse mortality (NRM), relapse, and overall survival (OS). Multivariate analyses controlled for relevant patient and transplant factors. Higher w1/2 TAC (≥10 ng/ml) in weeks 1-2 had no association with aGVHD III/IV (35% vs. 35%, P = 0.71). Higher TAC levels during w3/4 were associated with a trend toward decreased aGVHD III-IV incidence (8% vs. 20%; P = 0.09). Multivariate analysis confirmed w3/4 TAC levels as protective against aGVHD III/IV (sub-Hazard Ratio [sHR] = 0.83, 95% CI: 0.70-0.98, P = 0.03) and NRM (sHR = 0.82, 95% CI: 0.71-0.95, P = 0.01), while w1/2 TAC levels had no significant impact on the above outcomes. TAC levels did not significantly impact OS or relapse. We conclude that following PTCy-based haplo-HSCT, higher TAC levels during weeks 3-4 may decrease aGVHD and NRM.
Author Stiefel, Olga
Machherndl-Spandl, Sigrid
Nikoloudis, Alexander
Rumpold, Holger
Wipplinger, Dagmar
Weltermann, Ansgar
Strassl, Irene
Clausen, Johannes
Petzer, Andreas
Kunte, Ameya
Groiss, Christina
Binder, Michaela
Buxhofer-Ausch, Veronika
Hasengruber, Petra
Aichinger, Christoph
Kaynak, Emine
Milanov, Robert
Mair, Lorenz
AuthorAffiliation 1 Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
2 Faculty of Medicine, Johannes Kepler University Linz, Linz, Austria
AuthorAffiliation_xml – name: 1 Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
– name: 2 Faculty of Medicine, Johannes Kepler University Linz, Linz, Austria
Author_xml – sequence: 1
  givenname: Alexander
  orcidid: 0000-0001-5713-6257
  surname: Nikoloudis
  fullname: Nikoloudis, Alexander
  email: alexander.nikoloudis@ordensklinikum.at, alexander.nikoloudis@gmail.com
– sequence: 2
  givenname: Veronika
  surname: Buxhofer-Ausch
  fullname: Buxhofer-Ausch, Veronika
– sequence: 3
  givenname: Ameya
  surname: Kunte
  fullname: Kunte, Ameya
– sequence: 4
  givenname: Christina
  surname: Groiss
  fullname: Groiss, Christina
– sequence: 5
  givenname: Lorenz
  surname: Mair
  fullname: Mair, Lorenz
– sequence: 6
  givenname: Christoph
  surname: Aichinger
  fullname: Aichinger, Christoph
– sequence: 7
  givenname: Michaela
  surname: Binder
  fullname: Binder, Michaela
– sequence: 8
  givenname: Petra
  surname: Hasengruber
  fullname: Hasengruber, Petra
– sequence: 9
  givenname: Emine
  surname: Kaynak
  fullname: Kaynak, Emine
– sequence: 10
  givenname: Dagmar
  surname: Wipplinger
  fullname: Wipplinger, Dagmar
– sequence: 11
  givenname: Robert
  surname: Milanov
  fullname: Milanov, Robert
– sequence: 12
  givenname: Irene
  surname: Strassl
  fullname: Strassl, Irene
– sequence: 13
  givenname: Olga
  surname: Stiefel
  fullname: Stiefel, Olga
– sequence: 14
  givenname: Sigrid
  surname: Machherndl-Spandl
  fullname: Machherndl-Spandl, Sigrid
– sequence: 15
  givenname: Holger
  surname: Rumpold
  fullname: Rumpold, Holger
– sequence: 16
  givenname: Ansgar
  surname: Weltermann
  fullname: Weltermann, Ansgar
– sequence: 17
  givenname: Andreas
  surname: Petzer
  fullname: Petzer, Andreas
– sequence: 18
  givenname: Johannes
  surname: Clausen
  fullname: Clausen, Johannes
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40808659$$D View this record in MEDLINE/PubMed
BookMark eNp1kstu1DAUhiNURKeFB2CDLLHpZoovsWOzQVWhF6kSm8I2OpOczHjkxMF2Ruqj8LY4nVJaECvf_v87F5-j4mDwAxbFW0ZPGauqD9QoobSpuGRCzdsXxYJJKZdCG35QLOb35Sw4LI5i3FJKK8Hlq-KwpJpqJc2i-Hm7QWL7EZpEfEcSNME720-RONyhi8QPBJopIbn8fvWZwNCSFGCIo4MhO6bU-B4jsQPZwOi8bXFItgFHNthD8qO3mM8kJuxJg849cUOyfvhIzkjAFHwcsUl2hzkEuLto4-viZQcu4puH9bj4dvHl9vxqefP18vr87GbZCGnSUgJvjQaxKlctV22pmGpRVqBoqUSullVaU9EBpRpB805VTAJgU3WCqq4S4ri43nNbD9t6DLaHcFd7sPX9hQ_rGkKuwWFdNbzEEhVIA2WOaFacCq05K0GvjOky69OeNU6rHtsmNyOAewZ9_jLYTb32u5pxISvKaCacPBCC_zFhTHVv49w4GNBPsRZcmJKWWpssff-XdOunkLu3V1HOhZiB756m9JjL7xHIArYX5J-PMWD3KGG0nses_mfMsud074mwxj9h_2_4BW8t08o
Cites_doi 10.1038/s41409-021-01528-y
10.3390/ph17050553
10.1080/01621459.1999.10474144
10.3390/cancers13040613
10.1016/0002-9343(80)90380-0
10.4212/cjhp.v73i1.2956
10.3324/haematol.2016.144139
10.1016/j.bbmt.2018.12.352
10.1007/978-0-387-21706-2
10.1016/j.leukres.2017.02.006
10.1053/j.seminoncol.2012.09.005
10.1016/j.bbmt.2005.09.004
10.1016/j.bbmt.2019.12.597
10.1016/j.bbmt.2020.05.001
10.3389/fphar.2023.1334440
10.1111/cts.12982
10.1177/17407745241267862
10.1038/bmt.2015.323
10.1016/j.jcyt.2024.02.003
ContentType Journal Article
Copyright The Author(s) 2025
The Author(s) 2025 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2025 2025 SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s) 2025
– notice: The Author(s) 2025 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2025 2025 SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
8FD
FR3
H94
K9.
P64
RC3
7X8
5PM
DOA
DOI 10.1177/09636897251366368
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList


MEDLINE
MEDLINE - Academic
Genetics Abstracts
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
Anatomy & Physiology
Biology
EISSN 1555-3892
ExternalDocumentID oai_doaj_org_article_7c24e4e6a59a43b49b20388214a8b99f
PMC12357010
40808659
10_1177_09636897251366368
10.1177_09636897251366368
Genre Journal Article
GroupedDBID ---
--K
0R~
0VX
1B1
29B
4.4
53G
54M
5GY
7X7
8FI
8FJ
AAEDT
AAEJI
AAGGD
AALRI
AAPEO
AAQGT
AAQXH
AAQXK
AASGM
AAXUO
ABDWY
ABJIS
ABQKF
ABQXT
ABUWG
ABVFX
ABWVN
ABYTW
ACARO
ACFMA
ACGBL
ACHEB
ACLHI
ACROE
ACRPL
ACVFH
ADBBV
ADCNI
ADEIA
ADMUD
ADNMO
ADOGD
ADTBJ
ADUKL
AENEX
AEUPX
AEWDL
AFCOW
AFDWT
AFKRA
AFKRG
AFPUW
AFRWT
AFYCX
AGQPQ
AJEFB
AJMMQ
AJUZI
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APTNG
AUTPY
AYAKG
BAWUL
BCNDV
BDDNI
BENPR
BPHCQ
BSEHC
BVXVI
CBRKF
CCPQU
CORYS
CQQTX
CS3
DC.
DU5
EBS
EJD
EMOBN
F5P
FDB
FEDTE
FGOYB
FYUFA
GROUPED_DOAJ
H13
HMCUK
HVGLF
HYE
HZ~
IHE
J8X
K.F
M41
NQ-
OK1
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
Q1R
R2-
R9-
ROL
RPM
RPZ
SAUOL
SCDPB
SCNPE
SFC
UHS
UKHRP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PUEGO
7T5
8FD
ALIPV
FR3
H94
K9.
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c359t-5a2d98a3b4bd26d4616de57a60463325178803fa008ea82f6715aaec7f306f733
IEDL.DBID AFRWT
ISSN 0963-6897
1555-3892
IngestDate Wed Aug 27 01:31:41 EDT 2025
Thu Aug 21 18:24:44 EDT 2025
Thu Aug 14 17:32:40 EDT 2025
Wed Aug 13 11:40:57 EDT 2025
Thu Aug 28 04:33:00 EDT 2025
Thu Aug 21 00:31:10 EDT 2025
Sun Aug 17 05:41:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords tacrolimus
haploidentical transplantation with posttransplant cyclophosphamide and tacrolimus mycophenolate mofetil
acute graft-versus-host-disease
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c359t-5a2d98a3b4bd26d4616de57a60463325178803fa008ea82f6715aaec7f306f733
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5713-6257
OpenAccessLink https://journals.sagepub.com/doi/full/10.1177/09636897251366368?utm_source=summon&utm_medium=discovery-provider
PMID 40808659
PQID 3239022330
PQPubID 4450831
ParticipantIDs doaj_primary_oai_doaj_org_article_7c24e4e6a59a43b49b20388214a8b99f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12357010
proquest_miscellaneous_3239404889
proquest_journals_3239022330
pubmed_primary_40808659
crossref_primary_10_1177_09636897251366368
sage_journals_10_1177_09636897251366368
PublicationCentury 2000
PublicationDate 20250800
PublicationDateYYYYMMDD 2025-08-01
PublicationDate_xml – month: 8
  year: 2025
  text: 20250800
PublicationDecade 2020
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: United States
– name: Thousand Oaks
– name: Sage CA: Los Angeles, CA
PublicationTitle Cell transplantation
PublicationTitleAlternate Cell Transplant
PublicationYear 2025
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Phan, Chavan, Beuttler, Benipayo, Magedman, Buchbinder, Tomaszewski, Yang 2021; 14
Im, Rashidi, Wang, Hemmer, MacMillan, Pidala, Jagasia, Pavletic, Majhail, Weisdorf, Abdel-Azim 2020; 26
Yao, Yang, Clark, Otoukesh, Cao, Ali, Arslan, Aldoss, Artz, Amanam, Salhotra 2022; 57
Filipovich, Weisdorf, Pavletic, Socie, Wingard, Lee, Martin, Chien, Przepiorka, Couriel, Cowen 2005; 11
Shulman, Sullivan, Weiden, McDonald, Striker, Sale, Hackman, Tsoi, Storb, Thomas 1980; 69
Ganetsky, Shah, Miano, Hwang, He, Loren, Hexner, Frey, Porter, Reshef 2016; 51
Marco, Molina, Guio, Julian, Fortuna, Fabregat-Zaragoza, Salas, Monge-Escartín, Riu-Viladoms, Carcelero, Roma 2024; 17
Fine, Gray 1999; 94
Gao, Liu, Zhang, Chen, Gao, Zhang, Liu, Kong, Zhong, Sun, Du 2017; 57
Sharma, Zhao, Ni, Elder, Puto, Benson, Rosko, Chaudhry, Devarakonda, Bumma, Khan 2021; 13
Trepte, Zhang, Sizemore, Holland, Solh, Morris, Bashey, Solomon 2020; 26
Seligson, Zhang, Zemanek, Johnson, VanGundy, Wang, Phelps, Roddy, Hofmeister, Li, Poi 2023; 14
McCurdy, Kasamon, Kanakry, Bolaños-Meade, Tsai, Showel, Kanakry, Symons, Gojo, Smith, Bettinotti 2017; 102
Przepiorka, Weisdorf, Martin, Klingemann, Beatty, Hows, Thomas 1995; 15
Luznik, O’Donnell, Fuchs 2012; 39
Therneau, Ou 2024; 21
Cheung, Wentzell, Trinacty, Giguère, Patel, Kekre, Nguyen 2020; 73
Huynh, Freeman, Marshall, Markstrom, Frame 2019; 25
Nikoloudis, Buxhofer-Ausch, Aichinger, Binder, Hasengruber, Kaynak, Wipplinger, Milanov, Strassl, Stiefel, Machherndl-Spandl 2024; 26
Wickham H. (e_1_3_3_15_2) 2016
e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
e_1_3_3_17_2
e_1_3_3_9_2
e_1_3_3_16_2
e_1_3_3_18_2
Przepiorka D (e_1_3_3_10_2) 1995; 15
e_1_3_3_13_2
e_1_3_3_24_2
e_1_3_3_12_2
e_1_3_3_23_2
e_1_3_3_14_2
e_1_3_3_25_2
e_1_3_3_2_2
e_1_3_3_20_2
Wickham H (e_1_3_3_19_2) 2024
e_1_3_3_4_2
e_1_3_3_11_2
e_1_3_3_22_2
e_1_3_3_3_2
e_1_3_3_21_2
References_xml – volume: 26
  issue: 3
  year: 2020
  article-title: Evaluation of tacrolimus levels and risk of graft-versus-host disease, relapse and non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide
  publication-title: Biol Blood Marrow Transplant
– volume: 57
  issue: 2
  year: 2022
  article-title: Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
  publication-title: Bone Marrow Transplant
– volume: 13
  start-page: 613
  issue: 4
  year: 2021
  article-title: Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem cell transplantation
  publication-title: Cancers (Basel)
– volume: 14
  issue: 4
  year: 2021
  article-title: Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus
  publication-title: Clin Transl Sci
– volume: 17
  start-page: 553
  issue: 5
  year: 2024
  article-title: Effects of CYP3A5 genotype on tacrolimus pharmacokinetics and graft-versus-host disease incidence in allogeneic hematopoietic stem cell transplantation
  publication-title: Pharmaceuticals (Basel)
– volume: 94
  start-page: 496
  issue: 446
  year: 1999
  end-page: 509
  article-title: A proportional hazards model for the subdistribution of a competing risk
  publication-title: J Am Stat Assoc
– volume: 26
  issue: 8
  year: 2020
  article-title: Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide
  publication-title: Biol Blood Marrow Transplant
– volume: 102
  start-page: 391
  issue: 2
  year: 2017
  end-page: 400
  article-title: Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
  publication-title: Haematologica
– volume: 57
  start-page: 27
  year: 2017
  end-page: 36
  article-title: Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation
  publication-title: Leuk Res
– volume: 69
  issue: 2
  year: 1980
  article-title: Chronic graft-versus-host syndrome in man
  publication-title: Am J Med
– volume: 25
  issue: 3
  year: 2019
  article-title: Evaluation of tacrolimus levels and risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant
  publication-title: Biol Blood Marrow Transplant
– volume: 21
  issue: 5
  year: 2024
  article-title: Using multistate models with clinical trial data for a deeper understanding of complex disease processes
  publication-title: Clin Trials
– volume: 14
  start-page: 1334440
  year: 2023
  article-title: CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation
  publication-title: Front Pharmacol
– volume: 39
  issue: 6
  year: 2012
  article-title: Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation
  publication-title: Semin Oncol
– volume: 11
  issue: 12
  year: 2005
  article-title: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
  publication-title: Biol Blood Marrow Transplant
– volume: 73
  start-page: 37
  issue: 1
  year: 2020
  end-page: 44
  article-title: Efficacy, safety, and practicality of tacrolimus monitoring after bone marrow transplant: assessment of a change in practice
  publication-title: Can J Hosp Pharm
– volume: 51
  issue: 4
  year: 2016
  article-title: Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation
  publication-title: Bone Marrow Transplant
– volume: 15
  issue: 6
  year: 1995
  article-title: 1994 consensus conference on acute GVHD grading
  publication-title: Bone Marrow Transplant
– volume: 26
  issue: 5
  year: 2024
  article-title: Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion
  publication-title: Cytotherapy
– ident: e_1_3_3_4_2
  doi: 10.1038/s41409-021-01528-y
– ident: e_1_3_3_8_2
  doi: 10.3390/ph17050553
– ident: e_1_3_3_16_2
  doi: 10.1080/01621459.1999.10474144
– ident: e_1_3_3_9_2
  doi: 10.3390/cancers13040613
– ident: e_1_3_3_12_2
  doi: 10.1016/0002-9343(80)90380-0
– ident: e_1_3_3_22_2
  doi: 10.4212/cjhp.v73i1.2956
– ident: e_1_3_3_18_2
– ident: e_1_3_3_3_2
  doi: 10.3324/haematol.2016.144139
– ident: e_1_3_3_7_2
  doi: 10.1016/j.bbmt.2018.12.352
– ident: e_1_3_3_17_2
  doi: 10.1007/978-0-387-21706-2
– ident: e_1_3_3_23_2
  doi: 10.1016/j.leukres.2017.02.006
– ident: e_1_3_3_2_2
  doi: 10.1053/j.seminoncol.2012.09.005
– volume: 15
  issue: 6
  year: 1995
  ident: e_1_3_3_10_2
  article-title: 1994 consensus conference on acute GVHD grading
  publication-title: Bone Marrow Transplant
– ident: e_1_3_3_11_2
  doi: 10.1016/j.bbmt.2005.09.004
– ident: e_1_3_3_20_2
  doi: 10.1016/j.bbmt.2019.12.597
– volume-title: ggplot2—elegant graphics for data analysis
  year: 2016
  ident: e_1_3_3_15_2
– ident: e_1_3_3_5_2
  doi: 10.1016/j.bbmt.2020.05.001
– ident: e_1_3_3_21_2
  doi: 10.3389/fphar.2023.1334440
– ident: e_1_3_3_25_2
  doi: 10.1111/cts.12982
– ident: e_1_3_3_13_2
– ident: e_1_3_3_14_2
  doi: 10.1177/17407745241267862
– ident: e_1_3_3_6_2
  doi: 10.1038/bmt.2015.323
– volume-title: dplyr: a grammar of data manipulation
  year: 2024
  ident: e_1_3_3_19_2
– ident: e_1_3_3_24_2
  doi: 10.1016/j.jcyt.2024.02.003
SSID ssj0007325
Score 2.4383337
Snippet The impact of early tacrolimus (TAC) blood levels on acute graft-versus-host disease (aGVHD) and transplant outcomes in adults undergoing haploidentical...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 9636897251366368
SubjectTerms Adolescent
Adult
Blood levels
Cyclophosphamide
Female
Graft vs Host Disease - blood
Graft vs Host Disease - drug therapy
Graft-versus-host reaction
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic stem cells
Humans
Immunosuppressive Agents - therapeutic use
Lymphocytes T
Male
Middle Aged
Multivariate analysis
Mycophenolic acid
Original
Retrospective Studies
Stem cell transplantation
Tacrolimus
Tacrolimus - blood
Tacrolimus - therapeutic use
Transplantation, Haploidentical - methods
Treatment Outcome
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQ4IGh5hBY0SAgkpIgmfnPbAmXFgRNFvUVOYqsrbZPVbnLgp_BvO-Mkyy4PceEW2Y5izXy2Z-KZbxh7WQfykb1IpQomFfWpTcsgbCq5R3O8rpwOMdrii5pfiM-X8nKn1BfFhA30wIPg3uoqF1545aR1gpfCljkRmOSZcKa0NtDui2fe5EyNe7DmuRzvMCO9EsJMGavxMOeKHvdOoUjW_ycL8_dAyZ1or3gAnd9n90bLEWbDjB-wW745ZEezBr3m6-_wCmIsZ_xJfshun01Pd3cIB4_YD0QFDImR0AboXEVFe677DSwpeGgDbQOu6jsPn77NP4Braugi-_kSFQBt3yE-_QYWDVy51bJdxCxf1DJE6td21S4oJxKIHBroSmDn7YiAdzCDte_W7ZTgiZ8YSFEesovzj1_fz9OxOENacWm7VLq8tsahRso6V7VQmaq91E4RBRknIjTcGXhwaGN4Z_KgdCad85VGcKigOX_EDpq28U8YaFE5bCuNr7nQRhoX0I9SQhGLss9kwt5MyipWAwdHkU005b9qNmFnpM7tQKLPjg0IqmIEVfEvUCXsZAJDMa7pTcFzbtHi4fw0YS-23bgaSZ6u8W0_jBG0KdqEPR6ws52JQOPcKIk9Zg9Ve1Pd72kWV5HxmxKaNXrOCXtNAPw5p7-K4en_EMMxu5NTueMY73jCDrp175-hDdaVz-NyuwHp6yyC
  priority: 102
  providerName: Directory of Open Access Journals
Title The impact of tacrolimus levels on acute GVHD and transplant outcomes in haploidentical hematopoietic stem cell transplantation: A retrospective analysis
URI https://journals.sagepub.com/doi/full/10.1177/09636897251366368
https://www.ncbi.nlm.nih.gov/pubmed/40808659
https://www.proquest.com/docview/3239022330
https://www.proquest.com/docview/3239404889
https://pubmed.ncbi.nlm.nih.gov/PMC12357010
https://doaj.org/article/7c24e4e6a59a43b49b20388214a8b99f
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe2TkjwgGDjIzAqIyGQkMLW-CvmBbWwUvEwoWmDvkVO4rBKbVy1ycP-FP5b7pyktDAknhLZjuzYP9tn393vCHmVF3hGtjwUsohDnp_qMC24DgWzII7nmVGFt7Y4l5Mr_mUqpnvEdb4wbQ-u36FZFbTIL9Y4u_E2-qRVMp6A3M1krBVszkzi64e6WiTNdXcXVQNTUD9dL1C1naFB5E3Yubftk4NIgXDSIwfD8cX3y83irZiP04oVhFhDqwi9tdKdrcwz_t8mpv5tbbllMuZ3sfEDcr8VP-mwwctDsmfLQ3I0LOHovbihr6k3CPU37Yfkzqh7u7fFWnhEfgK0aONdSV1BK5Nh5J9FvaZztEBaU1dSk9WVpZ-_TT5RU-a08hTqcxhF6uoKOtuu6ayk12Y5dzPvKgxQoZ4_1i3dDB0rKTJMU9QrbH3tYfSeDunKVivXeYlCFQ2zyiNyNT67_DgJ2wgPYcaErkJholzHhqU8zSOZczmQuRXKSOQxY8imBssLKwwIKtbEUSHVQBhjMwUIk4Vi7DHpla60TwlVPDOQlsY2Z1zFIjYFHMYkl0jFbAciIG-7wUqWDZFHMui4zv8c2YCMcDg3BZGD2ye41Y-kndKJyiJuuZVGaMPhF3QaIbVONOAmTrUuAnLcgSHpYJ2wiGkQmxg7DcjLTTZMaexPU1pXN2U4rqw6IE8a7GxawkHCj6WAnHgHVTtN3c0pZ9eeNhy9ohUcvwPyBgH4u03_7IZn_13yObkbYWBkbxl5THrVqrYvQFqr0j7ZV1PVb-cZPEdn518v-v7u4xeILT3A
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZgKwQcELQ8AgWMhEBCStXEb25bYFmg9IC20FvkJA5daZusdpMDP4V_y4zzYBeKxM3yI3E8n-2ZeOYzIc_zAm1kx0MhCx3y_NCEacFNKJgDdTzPrCq8t8WJnJ7yj2firPOqxFiYbgTXB-hWBT3yi_Uwu5EpCRAjtVGwLzOJyatkh8OupUdkZzz58m02rMOK-StXsUGILbozzUsfsrUrefL-yzTOvx0nN7y__IY0uU1udZokHbeiv0OuuHKX7I1LsKIvftAX1Pt2-p_mu-TaUZ-6uUFAuEd-AkpoGyhJq4LWNsNLfC6aNV2gM9GaViW1WVM7-v7r9C21ZU5rz4a-AIHQqqlh3Nyazkt6bpeLau6jfkHq1FPBVstqjjGSFMmiKR4RbLT2iHhNx3Tl6lXVB3zCK1qSlLvkdPJu9mYadpc1hBkTpg6FjXOjLUt5mscy5zKSuRPKSqQkY0iMBisFKyzoHM7quJAqEta6TAFYZKEYu0dGZVW6B4QqnlnIS7XLGVdaaFuAXSW5RFZlF4mAvOqFlSxbTo4k6mnL_5RsQI5QnENFpNP2GdXqe9LNzkRlMXfcSSuM5fAJJo2RJSeOuNWpMUVA9nswJD1CExYzAxoQY4cBeTYUw-zE8bSlq5q2DsdF0gTkfoudoScclHUtBZToLVRtdXW7pJyfewZwDHBWYEkH5CUC8Hef_jkMD_-75lNyfTr7fJwcfzj59IjciPG-Y-_wuE9G9apxj0EJq9Mn3Wz7BfPDJ7M
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegEwgeEGzAAgOMhEBCCmvir5i3jlHKhyaENra3yEnsrVKXVG3ywJ_Cf8udk5QWhsRb5I_E8d3Zd_bd7wh5UTi0kS0PhXRJyIuhDjPHdSiYBXW8yI1y3tviSE5O-KczcdYduGEsTDeDyzfoVgUj8os1Sve8cPvdHeM-qN1MJlrB3swkPl4nW5wrPhyQrdH42-nxai1WzKddxQ4h9ujuNa98ycbO5AH8r9I6_3aeXPMA85vS-C6502mTdNSS_x65ZsttsjMqwZK-_EFfUu_f6Q_Ot8mNg_7p9hoI4Q75CZxC22BJWjlamxwT-Vw2SzpDh6IlrUpq8qa29MP3ySE1ZUFrj4g-A6LQqqlh7uySTkt6Yeazauojf4Hy1MPBVvNqinGSFAGjKV4TrPX2XPGWjujC1ouqD_qET7RAKffJyfj98btJ2CVsCHMmdB0KExc6MSzjWRHLgstIFlYoIxGWjCE4GqwWzBnQO6xJYidVJIyxuQKGkU4x9oAMyqq0u4QqnhsoyxJbMK4SkRgHtpXkEpGVbSQC8ronVjpvcTnSqIcu_5OyATlAcq4aIqS2L6gW52knoanKY265lUZow-EXdBYjUk4ccZNkWruA7PXMkPZcmrKYadCCGBsG5PmqGiQU59OUtmraNhwXSh2Qhy3vrEbCQWFPpICaZIOrNoa6WVNOLzwKOAY5K7CmA_IKGfD3mP45DY_-u-UzcvPr4Tj98vHo82NyK8aUx97ncY8M6kVjn4AeVmdPO2H7BUkpKMM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+tacrolimus+levels+on+acute+GVHD+and+transplant+outcomes+in+haploidentical+hematopoietic+stem+cell+transplantation%3A+A+retrospective+analysis&rft.jtitle=Cell+transplantation&rft.au=Nikoloudis%2C+Alexander&rft.au=Buxhofer-Ausch%2C+Veronika&rft.au=Kunte%2C+Ameya&rft.au=Groiss%2C+Christina&rft.date=2025-08-01&rft.eissn=1555-3892&rft.volume=34&rft.spage=9636897251366368&rft_id=info:doi/10.1177%2F09636897251366368&rft_id=info%3Apmid%2F40808659&rft.externalDocID=40808659
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0963-6897&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0963-6897&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0963-6897&client=summon